RSS Feed
- Netflix: The Biggest Empty Promise Since Enron?
- Why Car Prices Vary From City To City
- Big Bank Phobia: Not Too Big to Fail
- Apple Should Still Fire Tim Cook
- Expect Your Health Care in Retirement to Hit $200,000
Article
Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
07:00AM 05/17/13
Video
Biotech's Next Big Thing -- ASCO II
TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
02:09PM 05/16/13
Article
ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine
Here's why Stimuvax didn't help lung cancer patients live longer.
06:00PM 05/15/13
Article
10 ASCO '13 Abstracts You Can Read Right Now
Get a head start on searching through ASCO abstracts with these 10 summaries.
06:00PM 05/15/13
Article
ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up
New data suggests Roche's GA101 is more potent than the blockbuster Rituxan.
06:00PM 05/15/13
Article
ASCO '13 Preview: Gilead's Big Cancer Debut
More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.
06:00PM 05/15/13
Article
ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors
A new class of immune-boosting drugs are showing great promise against melanoma, lung and kidney cancers.
06:00PM 05/15/13
Article
SEC Is Investigating Spectrum Pharma
Regulators have issued a subpoena to Spectrum for information related to the steep cut in Fusilev sales in 2013.
07:19AM 05/13/13
Article
Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
07:00AM 05/10/13
Video
Biotech's Next Big Thing: ASCO
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
09:39AM 05/09/13